Acer Drug Patent Portfolio

Acer owns 1 orange book drug protected by 3 US patents Given below is the list of Acer's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11154521 Palatable compositions including sodium phenylbutyrate and uses thereof 17 Oct, 2036
Active
US11202767 Methods of treating urea cycle disorders and maple syrup urine disease 17 Oct, 2036
Active
US11433041 Palatable compositions including sodium phenylbutyrate and uses thereof 17 Oct, 2036
Active


Given below is the list of recent legal activities going on the following drug patents of Acer.

Activity Date Patent Number
Patent litigations
Change in Power of Attorney (May Include Associate POA) 02 Apr, 2024 US11154521
Email Notification 02 Apr, 2024 US11433041
Change in Power of Attorney (May Include Associate POA) 02 Apr, 2024 US11202767
Change in Power of Attorney (May Include Associate POA) 02 Apr, 2024 US11433041
Recordation of Patent Grant Mailed 06 Sep, 2022 US11433041
Patent Issue Date Used in PTA Calculation 06 Sep, 2022 US11433041
Email Notification 18 Aug, 2022 US11433041
Issue Notification Mailed 17 Aug, 2022 US11433041
Application Is Considered Ready for Issue 04 Aug, 2022 US11433041
Dispatch to FDC 04 Aug, 2022 US11433041
Issue Fee Payment Received 26 Jul, 2022 US11433041
Issue Fee Payment Verified 26 Jul, 2022 US11433041
Email Notification 20 Jul, 2022 US11433041
Electronic Review 20 Jul, 2022 US11433041
Mail Notice of Allowance 20 Jul, 2022 US11433041


Acer's Family Patents

Acer drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 24.1% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Acer Drug List

Given below is the complete list of Acer's drugs and the patents protecting them.


1. Olpruva

Olpruva is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11154521 Palatable compositions including sodium phenylbutyrate and uses thereof 17 Oct, 2036
(12 years from now)
Active
US11202767 Methods of treating urea cycle disorders and maple syrup urine disease 17 Oct, 2036
(12 years from now)
Active
US11433041 Palatable compositions including sodium phenylbutyrate and uses thereof 17 Oct, 2036
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olpruva's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List